Injectable pill’s link with HIV
Print Edition
WOMEN who use a specific type of injectable birth control have a slightly higher risk of HIV infection than those who take the pill, said a study yesterday.
While the authors noted the link was “statistically significant,” they warned it was not enough on its own to justify a complete withdrawal of the drug commonly known by its brand name, Depo-Provera, used by millions of women.
The health risks of pulling the medicine from shelves may far outweigh the potential preventable HIV infections, the authors argued in a paper published in the prestigious medical journal, The Lancet Infectious Diseases.
A meta-analysis of 12 studies involving nearly 40,000 women in sub-Saharan Africa showed that use of depot medroxyprogesterone acetate (DMPA) “increases a woman’s chance of becoming infected with HIV by 40 percent compared with women using other contraceptive methods or no method,” said a statement.
“Although statistically significant, this represents only a moderate increase in relative risk,” it added.
The increase in risk was somewhat lower among women “in the general population” than for those already at higher HIV risk, like sex workers.
The analysis showed no increased risk for users of other contraceptive drugs. All the studies had factored in condom use.
“The moderate elevation in risk observed in our study is not enough to justify a complete withdrawal of DMPA for women in the general population,” said study co-author Lauren Ralph of the University of California at Berkeley.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
